Estimates Revisions Relmada Therapeutics, Inc.
Stocks
RLMD
US75955J4022
Biotechnology & Medical Research
|
Real-time Estimate
Cboe BZX
19:57:58 21/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 4.630 USD | -0.22% |
|
-3.65% | -4.24% |
| 08-07 | Relmada Therapeutics, Inc., Q2 2026 Earnings Call, Aug 06, 2026 | |
| 08-07 | Relmada Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | - | - | ||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
- Stock Market
- Stocks
- RLMD Stock
- Consensus Relmada Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
